Company Description

Rock Immune is an early-stage biopharmaceutical company focused on the development and commercialization of diphtheria toxin-based recombinant immunotoxins for treatment of cancer & autoimmune diseases. Their leading drug candidate is CCR4-IL2 bispecific immunotoxin (CCR4-IL2 IT) for Cutaneous T-cell Lymphoma (CTCL).